Jonathan Monson
Summary
Jonathan Monson has served as Boston Scientific’s Executive Vice President and Chief Financial Officer since June 30, 2025, after more than a decade in the company’s finance and accounting organization. ([bostonscientific.com](https://www.bostonscientific.com/en-US/about-us/leadership/jonathan-monson.html?utm_source=openai))
Biography
Monson became Boston Scientific’s Executive Vice President and Chief Financial Officer effective June 30, 2025, succeeding Dan Brennan. His responsibilities include corporate finance, treasury, tax, investor relations, global controllership, internal audit, and corporate business development. ([news.bostonscientific.com](https://news.bostonscientific.com/2025-04-23-Boston-Scientific-Chief-Financial-Officer-CFO-Dan-Brennan-to-retire-Jon-Monson%2C-senior-vice-president%2C-Investor-Relations-to-succeed-Brennan?utm_source=openai)) Before becoming CFO, Monson was Senior Vice President of Investor Relations and previously served as the company’s global controller and chief accounting officer from July 2019 to March 2024. He also served as Vice President and Controller of the Urology business from 2016 to 2019 and as Vice President of Corporate Accounting from 2008 to 2016. Before joining Boston Scientific, he was a senior auditor at Arthur Andersen LLP; he holds a degree in economics and accounting from the College of the Holy Cross and is a certified public accountant. ([bostonscientific.com](https://www.bostonscientific.com/en-US/about-us/leadership/jonathan-monson.html?utm_source=openai))
Notable achievements
- Advanced through several finance, accounting, business-unit controller, and investor-relations roles before being appointed CFO, giving him long tenure inside Boston Scientific’s finance organization. ([bostonscientific.com](https://www.bostonscientific.com/en-US/about-us/leadership/jonathan-monson.html?utm_source=openai))
- Previously led global controllership and served as chief accounting officer, with responsibility for accounting and financial-planning processes. ([bostonscientific.com](https://www.bostonscientific.com/en-US/about-us/leadership/jonathan-monson.html?utm_source=openai))
- Was selected for the CFO role as part of an internal succession plan following Dan Brennan’s retirement, with the company describing the transition as a coordinated handoff. ([news.bostonscientific.com](https://news.bostonscientific.com/2025-04-23-Boston-Scientific-Chief-Financial-Officer-CFO-Dan-Brennan-to-retire-Jon-Monson%2C-senior-vice-president%2C-Investor-Relations-to-succeed-Brennan?utm_source=openai))
- Signed Boston Scientific’s 2025 Form 10-K as Executive Vice President and Chief Financial Officer; the company’s independent auditor reported an unqualified opinion on internal control over financial reporting. ([publicnow.com](https://www.publicnow.com/view/E7663A90B4DAFBFB842AE0D0848DC085CED11F83?utm_source=openai))
Problem areas / controversies
- Monson has a relatively short public track record as a chief financial officer because he assumed the role on June 30, 2025; his performance in capital allocation and long-term financial stewardship remains less established than that of his predecessor. ([bostonscientific.com](https://www.bostonscientific.com/en-US/about-us/leadership/jonathan-monson.html?utm_source=openai))
- The CFO organization operates amid Boston Scientific’s disclosed product-liability, regulatory, intellectual-property, commercial, and securities matters, which can affect reserves, cash use, reporting, and investor communications. The filings do not attribute those matters to personal misconduct by Monson. ([publicnow.com](https://www.publicnow.com/view/E7663A90B4DAFBFB842AE0D0848DC085CED11F83?utm_source=openai))
- The company has continued to face device-safety issues, including recalls and FDA alerts, creating additional financial-reporting, remediation, and risk-management responsibilities for the finance organization. ([accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/resCollection_2.cfm?ID=211663&utm_source=openai))